Full Text View
Tabular View
No Study Results Posted
Related Studies
EXTEND (Eltrombopag Extended Dosing Study)
This study is ongoing, but not recruiting participants.
Study NCT00351468   Information provided by GlaxoSmithKline

First Received on July 10, 2006.   Last Updated on February 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
More general conditions related to this trial
Autoimmune Diseases
Blood Coagulation Disorders
Blood Platelet Disorders
Hematologic Diseases
Hemorrhage
Hemorrhagic Disorders
Immune System Diseases
Pathologic Processes
Signs and Symptoms
Skin Manifestations
Thrombocytopenia
Thrombotic Microangiopathies
Interventions listed in this trial
eltrombopag olamine (SB-497115-GR)
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services